Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis
Aim: The role of tumor burden (TB) for patients with non-small cell lung cancer (NSCLC) receiving immunotherapy is still unknown. The aim of this analysis was to analyze the prognostic value of TB in a real-world sample of advanced NSCLC patients. Methods: Sixty-five consecutive patients with advanc...
Saved in:
Main Authors: | Edoardo Lenci (Author), Giulia Marcantognini (Author), Valeria Cognigni (Author), Alessio Lupi (Author), Silvia Rinaldi (Author), Luca Cantini (Author), Ilaria Fiordoliva (Author), Anna Lisa Carloni (Author), Marco Rocchi (Author), Lina Zuccatosta (Author), Stefano Gasparini (Author), Rossana Berardi (Author) |
---|---|
Format: | Book |
Published: |
Open Exploration Publishing Inc.,
2021-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC
by: Luca Cantini, et al.
Published: (2021) -
Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients
by: Luigi Della Gravara, et al.
Published: (2021) -
Impact of NSCLC metabolic remodeling on immunotherapy effectiveness
by: Lulu Lv, et al.
Published: (2022) -
The role of immunotherapy in early-stage and metastatic NSCLC
by: Attila Lieber, et al.
Published: (2024) -
The role of chemoradiotherapy and immunotherapy in stage III NSCLC
by: Zsuzsanna Orosz, et al.
Published: (2024)